Table 2.

Overall objective response by KRAS status (central assessment)

Low/Negative EGFRHigh EGFR
All patientsWT KRAS*MT KRAS*All patientsWT KRASMT KRAS
KRAS ITT analysis sets, n20394771858682
Best objective response, n (%)
    Partial response8 (4)8 (9)05 (3)5 (6)0
    Stable disease65 (32)44 (47)7 (9)43 (23)30 (35)9 (11)
    Disease progression101 (50)32 (34)56 (73)106 (57)40 (47)57 (70)
    Unevaluable/Not done29 (14)10 (10)14 (18)31 (17)11 (12)16 (19)
Response rate (%)3.98.502.75.80
95% CI§1.7-7.63.7-16.10.0-4.70.9-6.21.9-13.00.0-4.4
  • *Patients without available EGFR status (n = 8) and with EGFR ≥10% (n = 3) in the Low/Negative EGFR study were included in the KRAS subsets.

  • Analysis based on assessments from a blinded central review of scans using modified WHO criteria.

  • Three additional patients without EGFR status in the Low/Negative EGFR study also had stable disease through week 16.

  • §Confidence intervals are based on the exact binomial probability (15).